AIM ImmunoTech (AIM) Competitors $2.36 -0.29 (-10.94%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.08 (+3.18%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AIM vs. OBSV, MTNB, MYNZ, BMRA, APM, GNPX, EVOK, ALZN, ACXP, and BCLIShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include ObsEva (OBSV), Matinas Biopharma (MTNB), Mainz Biomed (MYNZ), Biomerica (BMRA), Aptorum Group (APM), Genprex (GNPX), Evoke Pharma (EVOK), Alzamend Neuro (ALZN), Acurx Pharmaceuticals (ACXP), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Its Competitors ObsEva Matinas Biopharma Mainz Biomed Biomerica Aptorum Group Genprex Evoke Pharma Alzamend Neuro Acurx Pharmaceuticals Brainstorm Cell Therapeutics ObsEva (NASDAQ:OBSV) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Do analysts prefer OBSV or AIM? AIM ImmunoTech has a consensus price target of $275.00, suggesting a potential upside of 11,552.54%. Given AIM ImmunoTech's stronger consensus rating and higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than ObsEva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OBSV or AIM more profitable? ObsEva has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. ObsEva's return on equity of -416.36% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets ObsEvaN/A -416.36% -92.01% AIM ImmunoTech -12,594.21%-421.73%-147.54% Which has preferable earnings & valuation, OBSV or AIM? AIM ImmunoTech has higher revenue and earnings than ObsEva. AIM ImmunoTech is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioObsEvaN/AN/A-$58.38M-$0.92N/AAIM ImmunoTech$146K12.35-$28.96M-$24.68-0.10 Do insiders and institutionals believe in OBSV or AIM? 17.5% of ObsEva shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer OBSV or AIM? In the previous week, AIM ImmunoTech had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for AIM ImmunoTech and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat AIM ImmunoTech's score of -0.38 indicating that ObsEva is being referred to more favorably in the media. Company Overall Sentiment ObsEva Neutral AIM ImmunoTech Neutral Which has more risk and volatility, OBSV or AIM? ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. SummaryObsEva beats AIM ImmunoTech on 8 of the 15 factors compared between the two stocks. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$1.80M$282.09M$5.70B$20.92BDividend YieldN/AN/A3.77%3.59%P/E Ratio-5.02N/A30.8628.16Price / Sales12.35577.86403.8856.93Price / CashN/A22.4425.2217.81Price / Book11.809.829.514.57Net Income-$28.96M-$115.81M$3.26B$993.62M7 Day Performance-8.88%2.20%4.50%2.33%1 Month Performance-74.49%-2.55%5.22%1.41%1 Year Performance-92.21%-6.73%31.92%13.75% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech1.3688 of 5 stars$2.36-10.9%$275.00+11,552.5%-91.3%$1.80M$146K-5.0220Gap UpHigh Trading VolumeOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050MTNBMatinas Biopharma1.5265 of 5 stars$1.51+2.0%N/AN/A$7.68MN/A-0.3130Short Interest ↓Gap UpMYNZMainz Biomed2.9789 of 5 stars$1.68+13.9%$14.00+735.8%-86.8%$7.67M$890K-0.0330Short Interest ↑Gap UpBMRABiomerica1.5723 of 5 stars$3.01+0.5%N/A+26.6%$7.65M$5.68M-1.3060Positive NewsShort Interest ↓APMAptorum Group0.6851 of 5 stars$1.41+1.4%N/A-56.6%$7.54M$430K0.0030Positive NewsGNPXGenprex1.8149 of 5 stars$0.23-3.2%N/A-67.3%$7.52MN/A0.0020News CoveragePositive NewsEarnings ReportShort Interest ↑Gap UpEVOKEvoke Pharma0.541 of 5 stars$4.97-0.5%N/A-11.0%$7.41M$11.59M-1.734Earnings ReportShort Interest ↓Gap DownALZNAlzamend Neuro2.7593 of 5 stars$2.47+1.2%$180.00+7,187.4%-87.0%$7.16MN/A0.004Short Interest ↑ACXPAcurx Pharmaceuticals3.0221 of 5 stars$4.65+4.6%$31.00+567.4%-87.3%$7.15MN/A-0.433Earnings ReportAnalyst UpgradeGap UpBCLIBrainstorm Cell Therapeutics2.4858 of 5 stars$0.64+1.0%N/A-87.8%$7.05MN/A-0.1940Short Interest ↓Gap Up Related Companies and Tools Related Companies OBSV Alternatives MTNB Alternatives MYNZ Alternatives BMRA Alternatives APM Alternatives GNPX Alternatives EVOK Alternatives ALZN Alternatives ACXP Alternatives BCLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AIM) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access